Pulmonology

Your daily dose of the clinical news you may have missed.

Dupilumab is the first agent approved to treat EoE in this vulnerable pediatric population.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.

Your daily dose of the clinical news you may have missed.

RSV vaccines from Pfizer-BioNTech and Moderna for adults aged 60 years and older aren't that different, so which would you recommend if a patient asks?

Use of dupilumab also eliminated the need for use of a rescue inhaler in more than one-third of treated patients and the number of inhalations needed for others.

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

Your daily dose of the clinical news you may have missed.

After hospital discharge, persons who had COVID-19 remained at greater risk of death and myriad adverse health outcomes compared with those who had seasonal flu.

Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.

Higher serum levels of the omega-3 fatty acids were associated with slowed disease progression and longer transplant-free survival in a new study.

Infections with the JN.1 Omicron descendent have doubled since mid-November and now comprise 1 in 5 cases of COVID-19 in the US.

If approved the 21-valent shot would be the first pneumococcal conjugate vaccine indicated specifically for adults.

Your daily dose of the clinical news you may have missed.

The coadministration of RSVpreF and seasonal influenza vaccine was found to generate robust immune responses in older adults, reported authors of new study.

Dupilumab reduced COPD exacerbations by more than one-third in the phase 3 NOTUS trial, matching outcomes from the earlier BOREAS study this year.

The finding implies the potential for virus transmission after initial recovery from the infection, according to study authors.

Your daily dose of the clinical news you may have missed.

A new meta-analysis found prevalence of asthma higher in countries with better air quality, higher income status, and health care access.

Data presented at CHEST 2023 shows treatment with hydrocortisone is associated with a decrease in morality among patients with community-acquired pneumonia.

Your daily dose of the clinical news you may have missed.

First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.

IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,

A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.

IDWeek 2023. New data shows non-Hispanic Black patients had a 13% lower likelihood of getting the influenza vaccine compared to non-Hispanic White patients.

Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.